Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
CYH
Community Health Systems, Inc.
CYH directly provides hospital inpatient and outpatient care services through a network of hospitals and related facilities.
|
$465.20M |
$3.31
-1.34%
|
|
KOPN
Kopin Corporation
CR3 medical headset and defense medical imaging/biometric sensing align with Medical Devices & Biometrics.
|
$462.37M |
$2.85
-3.23%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$462.34M |
$8.03
+0.94%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$462.05M |
$4.82
-2.03%
|
|
BCYC
Bicycle Therapeutics plc
Company's core focus is oncology with Bicycle Molecule platform and multiple lead oncology programs.
|
$460.20M |
$6.63
+0.08%
|
|
KIDS
OrthoPediatrics Corp.
Directly manufactures pediatric orthopedic implants and devices (plates, screws, growing rods, braces), the core product category for the company.
|
$459.10M |
$18.27
-2.43%
|
|
ENGN
enGene Holdings Inc.
engGene's core platform is non-viral gene therapy delivery (DDX platform) and its lead asset is a gene therapy product, placing it squarely in Gene Therapy.
|
$451.00M |
$8.93
+5.06%
|
|
MLAB
Mesa Laboratories, Inc.
Clinical Genomics hardware (MassARRAY) is diagnostic equipment used in regulated lab environments, fitting Diagnostic Equipment.
|
$446.66M |
$81.02
-3.87%
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$443.24M |
$16.68
+4.97%
|
|
STKL
SunOpta Inc.
The company functions as a co-manufacturer and private label partner, providing manufacturing services to brands and retailers.
|
$439.65M |
$3.69
-1.21%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$438.46M |
$1.49
-0.34%
|
|
BWAY
BrainsWay Ltd.
Core product: BrainsWay's Deep TMS neuromodulation devices.
|
$436.66M |
$22.84
-1.08%
|
|
MG
Mistras Group, Inc.
MG provides Laboratory Testing & Advisory Services as part of its inspection and testing offerings.
|
$433.65M |
$13.62
+1.23%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$433.12M |
$7.30
-0.48%
|
|
IMMP
Immutep Limited
Immutep is focused on immunology therapeutics, including LAG-3 modulation for cancer and autoimmune diseases.
|
$429.40M |
$2.96
-0.84%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$425.18M |
$1.19
+0.42%
|
|
CLPT
ClearPoint Neuro, Inc.
ClearPoint's core offerings include neurosurgical navigation hardware and related surgical equipment (e.g., ClearPoint system, Prism Laser Therapy, Velocity Alpha drill).
|
$424.14M |
$15.31
+0.03%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$424.12M |
$15.09
-1.02%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$421.78M |
$8.18
-2.10%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$421.38M |
$17.15
-2.44%
|
|
ETON
Eton Pharmaceuticals, Inc.
KHINDIVI (ET-400), ET-600, ET-700, and ET-800 involve oral/ready formulations (e.g., desmopressin, hydrocortisone, zinc) consistent with the Oral Small Molecule Therapeutics category.
|
$414.60M |
$15.62
-5.42%
|
|
CYBN
Cybin Inc.
Company's pipeline focuses on neuropsychiatric drug development (MDD, GAD) with CYB003/CYB004.
|
$413.12M |
$8.30
+1.53%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$411.93M |
$5.23
-1.51%
|
|
ADCT
ADC Therapeutics S.A.
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), directly aligning with the Antibody-Drug Conjugates category.
|
$411.75M |
$3.62
+1.54%
|
|
ANGO
AngioDynamics, Inc.
Core product category: vascular intervention devices, including Auryon, AlphaVac, and AngioVac.
|
$406.23M |
$9.96
-0.90%
|
|
AKBA
Akebia Therapeutics, Inc.
Vafseo (vadadustat) is Akebia's core product, an oral small-molecule therapeutic (HIF-PHI) for CKD anemia, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$403.02M |
$1.51
+1.68%
|
|
RCKT
Rocket Pharmaceuticals, Inc.
Direct gene therapy platform encompassing ex vivo LV and in vivo AAV modalities.
|
$402.48M |
$3.73
-3.87%
|
|
CERS
Cerus Corporation
Cerus' INTERCEPT Blood System is a medical device platform; primary product is a device used in transfusion safety.
|
$394.90M |
$2.04
-2.15%
|
|
AURA
Aura Biosciences, Inc.
Aura's lead oncology program bel-sar is a cancer therapy, targeting solid tumors and advancing in Phase 3.
|
$393.22M |
$6.16
-2.69%
|
|
TOI
The Oncology Institute, Inc.
Company operates community clinics and infusion suites (Outpatient/ASC Operators).
|
$390.85M |
$4.20
-2.67%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics' core business is developing allogeneic cell therapy platforms and products (OpRegen, OPC1, ReSonance ANP1).
|
$390.49M |
$1.72
-2.56%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$389.92M |
$3.87
-37.76%
|
Showing page 18 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
